Partner Headlines - ARNA

  1. Markets Marginally Lower Ahead Of Earnings Season

    Benzinga
  2. Arena Pharmaceutical Shares Dive On News CEO Sold 40% Of His ...

    Benzinga
  3. Benzinga's Top #PreMarket Losers

    Benzinga
  4. Events Scheduled for Week of Jun. 16th to Jun. 20th

    Benzinga
  5. FDA delays Orexigen drug

    IBD
  6. Is Arena Pharmaceuticals A Biotech Stock To Watch?

    Benzinga
  7. Orexigen Obesity Drug Decision Delayed By FDA

    IBD
  8. Orexigen Shares Plummet Following FDA Decision; Competition Gets ...

    Benzinga
  9. Arena Pharma Posts Q1 Loss Of $0.12/Share, Misses By ~$0.02/Share

    Benzinga
  10. Earnings Scheduled For May 12, 2014

    Benzinga
  11. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  12. Benzinga's Top #PreMarket Losers

    Benzinga
  13. Earnings Scheduled For February 27, 2014

    Benzinga
  14. Bad Earnings Weigh In On Diet Stocks

    Benzinga
  15. Top Trending Tickers On StockTwits For February 14

    Benzinga
  16. #PreMarket Primer: Friday, February 14: A Turnaround

    Benzinga
  17. Arena Pharmaceuticals Announces Filing for Marketing Authorization ...

    Benzinga
  18. Celgene To Release Earnings At J.P. Morgan Event Mon.

    IBD
  19. The Top Five Drug Launches Of 2013

    IBD
  20. (ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance ...

    GuruFocus
  21. Benzinga's Top #PreMarket Gainers

    Benzinga
  22. Market Wrap For November 11: Relative Quiet as Traders and Investors ...

    Benzinga
  23. Market Wrap For November 8: Markets Erase Thursday's Losses; ...

    Benzinga
  24. Arena Pharmaceuticals, Eisai Expand Marketing and Supply Agreement ...

    Benzinga
  25. Nasdaq Leads Stocks Lower; Twitter IPO Opens To 80% Gain

    IBD
  26. How Arena’s “$3 Billion” Belviq Withered

    YCharts
  27. Benzinga's Top #PreMarket Losers

    Benzinga
  28. Market Wrap For Tuesday, October 15: Earnings Reports And White ...

    Benzinga
  29. Mid-Afternoon Market Update: Tumi Holdings Rises Amid Market ...

    Benzinga
  30. Mid-Morning Market Update: Markets Slip; Citigroup Profit Misses ...

    Benzinga
  31. UPDATE: Arena Says Eisai Will Double BELVIQ Sales Force to 4 ...

    Benzinga
  32. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and ...

    Benzinga
  33. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD
  34. Benzinga's Top Pre-Market Losers

    Benzinga
  35. Market Wrap For September 30: Debt Ceiling And Government Shutdown ...

    Benzinga
  36. Mid-Afternoon Market Update: Mellanox Rallies As Market Remains ...

    Benzinga
  37. Mid-Day Market Update: Dow Falls Over 100 Points; Active Network ...

    Benzinga
  38. Mid-Morning Market Update: Markets Open Lower; Cal-Maine Q1 Net ...

    Benzinga
  39. UPDATE: Credit Suisse Lowers PT on Arena Pharmaceuticals Following ...

    Benzinga
  40. Arena Pharma Offers Update on Eisai Launch of BELVIQ, Says Placing ...

    Benzinga
  41. Stocks Hitting 52-Week Lows

    Benzinga
  42. BMO Considers Recent Sales Data on Arena's Belviq, Maintains ...

    Benzinga
  43. CEO Shift Aside, Whose Weight-Loss Pill’s Ahead

    YCharts
  44. Stocks Hitting 52-Week Lows

    Benzinga
  45. Stocks Hitting 52-Week Lows

    Benzinga
  46. Arena Pharma Reports Closing of Phase 1b Clinical Trial for APD811

    Benzinga
  47. Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, ...

    Benzinga
  48. It's Hard to Sell a Pill That Nobody's Heard Of

    YCharts
  49. Weekly Preview: Earnings Season Continues, Fed In Focus, Economic ...

    Benzinga
  50. Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

    Benzinga
  51. Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

    Benzinga
  52. Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

    Benzinga
  53. Mid-Afternoon Market Update: Markets All Green, Research in Motion ...

    Benzinga
  54. Mid-Day Market Update: GenCorp Rises, Markets Erasing Losses

    Benzinga
  55. Mid-Morning Market Update: Verizon Misses Big on Earnings, Research ...

    Benzinga
  56. Vivus fell 4.2% to 13.72

    IBD
  57. Vivus Stock Drops On Downgrade; Rival Arena Rises

    IBD
  58. Measuring Social Network Buzz Over Pharma Stocks

    YCharts
  59. Vivus Stock Jumps On Latest Qsymia Shipment Numbers

    IBD
  60. Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

    Benzinga
  61. Benzinga's Top Pre-Market Gainers

    Benzinga
  62. The Best Small Cap Performers of 2012

    Benzinga
  63. Vivus Soars On Qsymia Anti-Obesity Drug Prescriptions

    IBD
  64. Acadia Pharma Rockets Higher on Study Results

    Benzinga
  65. Vivus Stock Soars As Aetna Adds Qsymia To Coverage

    IBD
  66. Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

    Benzinga
  67. Arena Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  68. UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT ...

    Benzinga
  69. Vivus Earnings Miss Estimates; Arena Waits In Wings

    IBD
  70. Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)

    Benzinga
  71. Arena Pharmaceuticals Initiates Phase 1 Multiple Dose Clinical ...

    Benzinga
  72. WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC

    GuruFocus
  73. Who Needs Diet and Exercise? Health Plans Cover New Vivus Obesity ...

    YCharts
  74. Vivus Expects EU To Reject Diet Drug, Shares Fall

    IBD
  75. Vivus Dives 11% After Warning EU May Not Back Obesity Drug

    FoxBusiness
  76. Stocks Finish Little Changed with Yahoo (YHOO) and FedEx (FDX) ...

    MarketIntelligenceCenter
  77. All Eyes On Vivus As Weight Loss Drug Hits Market

    YCharts
  78. Short Sellers Shy Away from Biotech Firms

    Benzinga
  79. Benzinga's Top Pre-Market Gainers

    Benzinga
  80. UPDATE: Credit Suisse Initiates Arena Pharmaceuticals at Underperform ...

    Benzinga
  81. Health Care Sector Wrap

    FoxBusiness
  82. Short Interest in Biotech Firms on the Rise

    Benzinga
  83. What Slims Down Fastest After Diet Drugs Are Approved by he FDA? ...

    YCharts
  84. Health Care Sector Wrap

    FoxBusiness
  85. Arena Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  86. Four Investment Options Presented by Obesity and Related Health ...

    YCharts
  87. Biotechs In Motion As New Drug Pipeline Brims

    IBD
  88. Who's Next Facebook? VCs Try Software, Internet Firms

    IBD
  89. Arena Pharmaceuticals (ARNA) Falls 8.3% After Rival Weight Loss ...

    MarketIntelligenceCenter
  90. Wednesday Market Movers

    Benzinga
  91. Vivus Stock Jumps 12.5% On Drug Approval

    IBD
  92. Benzinga's Top Pre-Market Losers

    Benzinga
  93. Drug Stocks Up On Glaxo, Par M&A And Gilead HIV Pill

    IBD
  94. Vivus Rises Ahead Of FDA Vote On Qnexa Diet Drug

    IBD
  95. Stocks Move Lower as Euro Zone and Earnings Worries Persist with ...

    MarketIntelligenceCenter
  96. Dendreon, Pharmacyclics and Other Biotech Takeover Targets

    Benzinga
  97. Benzinga's Top Pre-Market Gainers

    Benzinga
  98. Arena Pharmaceuticals Inc. (ARNA) SVP, Finance and CFO Robert ...

    GuruFocus
  99. Health Care Sector Wrap

    FoxBusiness
  100. From Earlier: Arena Pharmaceuticals Promotes Craig M. Audet to ...

    Benzinga
Trading Center